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ExECUTivE sUmmaRy/absTRaCT
Improved and durable control of hypertension is a global 
priority for healthcare providers and policymakers. There 
are several lifestyle measures that are proven to result 
in improved blood pressure (BP) control. Moreover, 
there is incontrovertible evidence from large scale 
randomised controlled trials (RCTs) that antihypertensive 
drugs lower BP safely and effectively in the long-term 
resulting in substantial reduction in cardiovascular 
morbidity and mortality. Importantly, however, evidence 
is accumulating to suggest that patients neither sustain 
long-term healthy behaviours nor adhere to lifelong 
drug treatment regimens and thus alternative measures 
to control hypertension warrant further investigation. 
Endovascular renal denervation (RDN) appears to hold 
some promise as a non-pharmacological approach to 
lowering BP and achieves renal sympathectomy using 
either radiofrequency energy or ultrasound-based 
approaches. This treatment modality has been evaluated 
in clinical trials in humans since 2009 but initial studies 
were compromised by being non-randomised, without 
sham control and small in size. Subsequently, clinical 
trial design and rigour of execution has been greatly 
improved resulting in recent sham-controlled RCTs 
that demonstrate short-term reduction in ambulatory 
BP without any significant safety concerns in both 
medication-naïve and medication-treated hypertensive 
patients. Despite this, the joint UK societies still feel 
that further evaluation of this therapy is warranted and 
that RDN should not be offered to patients outside of 
the context of clinical trials. This document reviews the 
updated evidence since our last consensus statement 
from 2014 and provides a research agenda for future 
clinical studies.
baCKgRoUnd and sCopE of ThE ConsEnsUs 
sTaTEmEnT
High blood pressure (BP) is the most important 
risk factor for cardiovascular (CV) disease globally 
and a major threat to society’s well-being, despite 
improved awareness and treatment of uncontrolled 
hypertension.1 While lifestyle modification and 
pharmacotherapy are effective in improving BP 
control and lowering the risk of CV events, there 
is increasing recognition that patients may not be 
able to sustain healthy behaviour in the long term 
nor do they always maintain persistent adherence to 
antihypertensive drug treatment regimens.2 Of late, 
there has been increasing focus on interventional 
measures to combat uncontrolled hypertension and 
a variety of novel technologies are currently being 
evaluated in clinical trials.3 These include sympath-
omodulatory approaches such as renal denervation 
(RDN), baroreflex activation therapy and endo-
vascular baroreflex modulation: of these RDN has 
been the focus of greatest interest and research and 
our consensus statement is limited to consideration 
of this therapeutic approach.
Initial studies using radiofrequency (RF) RDN 
indicated some promise for the therapy in patients 
with resistant hypertension (RHTN) leading to 
a joint UK societies (JUKS) 2012 consensus state-
ment recommending that RDN be considered as an 
additional component of the National Institute for 
Health and Care Excellence (NICE) hypertension 
treatment algorithm at step 5.4–6 This meant that 
RDN would only be considered as a ‘standard of 
care’ invasive approach to treat RHTN in patients 
who had failed to respond to conventional phar-
macological measures and who were managed by 
hypertension experts. In the UK, plans were in 
place to cautiously adopt RDN via the ‘commis-
sioning through evaluation’ approach that had 
been successfully utilised in the case of transcath-
eter aortic valve replacement therapy in order to 
prevent widespread uptake of a potentially expen-
sive and not yet fully tested therapy for which the 
long-term risks were not established. However, 
these plans were halted following the publication 
of the SYMPLICITY HTN-3 randomised controlled 
study which failed to show a benefit of RF RDN 
over sham therapy in patients with RHTN.7
The publication prompted the JUKS to reconvene 
to produce a 2014 consensus statement which placed 
a moratorium on the use of RDN in routine clinical 
practice in the UK until further favourable evidence 
had emerged.8 The consensus statement outlined a 
number of failings of the clinical studies of RDN to 
date, as well as making a series of recommendations 
for future studies. These recommendations were 
reiterated and expanded on in international guid-
ance derived from the European Clinical Consensus 
Conferences with both documents taking into 
account recent research findings which gave greater 
detail of renal nerve microanatomy in humans, 
 o
n
 15 July 2019 by guest. Protected by copyright.
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2019-315098 on 10 July 2019. Downloaded from 
2 Lobo MD, et al. Heart 2019;0:1–8. doi:10.1136/heartjnl-2019-315098
Review
improved technical approaches for RDN and meticulous atten-
tion to rigorous trial design and execution in order to eliminate 
medication instability, BP variability and procedural inadequacy 
while mandating use of blinded end points (ambulatory systolic 
blood pressure (ASBP)).9 10 This led to new and improved clin-
ical trials of RDN utilising input from experts in the field to lead 
on both the design and execution of the studies in collabora-
tion with commercial sponsors. Several of these proof-of-prin-
ciple studies have now been presented and published and they 
demonstrate the short-term efficacy and safety of endovascular 
RDN performed using RF or ultrasound (US) energy; JUKS now 
consider the new evidence that they provide.
spyRaL sTUdy pRogRammE
Early RDN studies were performed using a unipolar catheter 
(Symplicity Flex; Medtronic, Galway, Ireland) delivering 4–6 
focal ablation points per renal artery with RF energy. Subse-
quently, Medtronic iterated the design of the catheter to provide 
circumferential ablation while appreciating the newly estab-
lished distribution of periarterial renal nerves.11 Furthermore, 
the procedural approach was refined to ensure RF energy was 
applied more distally in the renal artery including branch/acces-
sory artery denervation.12–14 The newly evolved Spyral multielec-
trode RF catheter (Medtronic, Galway, Ireland) paired with the 
Symplicity G3 RF RDN generator (Medtronic, Minneapolis, 
MN, USA) was put to the test in the SPYRAL study programme 
which initiated a global, multicentre approach to studying RDN 
in hypertensive patients.15
spyRaL hTn-off mEd
This multicentre, prospective, randomised, controlled, single-
blind study of RDN recruited patients from 21 centres in the 
USA, Europe, Australia and Japan.16 The design was a non-pow-
ered proof-of-concept trial with prespecified analyses at 40, 60, 
80 and 100 patients as it was felt that the reduction in BP and 
variability of the ASBP primary endpoint were not known in this 
hitherto untested patient group with mild-to-moderate hyperten-
sion. Patients between the age of 20 and 80 years were selected 
with office systolic blood pressure (SBP) of 150–180 mm Hg and 
office diastolic blood pressure (DBP) ≥90 mm Hg. The study 
participants were also required to have 24 hours mean ASBP of 
140–170 mm Hg at initial screening and following a medication 
washout period of 3–4 weeks. Evaluation of medication usage 
was undertaken using tandem high-performance liquid chroma-
tography (HPLC) and mass spectroscopy of urine and plasma 
samples by an independent laboratory. Patients who fulfilled 
inclusion criteria underwent a renal angiogram to ensure anatom-
ical enrolment criteria were met and then were randomised on 
a 1:1 basis to RDN versus sham therapy. Great efforts were 
made to ensure adequate blinding of patients including use of 
conscious sedation, sensory isolation (with blindfolding and 
music) and successful blinding was confirmed with the use of an 
established blinding index.17
The Symplicity SPYRAL catheter was used to provide circum-
ferential four quadrant RF RDN undertaken by a single oper-
ator in each trial centre (to minimise procedural variability) 
and with proctoring. All accessible renal arteries, branches 
and accessory arteries in a size range of 3–8 mm were targeted 
according to detailed prespecified treatment plans that were 
agreed between operators and expert proctors, who were 
present to ensure a standardised treatment approach within 
each procedure.
Patients were required to remain off antihypertensive medi-
cation for a period of 3 months following randomisation. In 
all 353 patients were enrolled of whom 80 were randomised 
to RDN (n=38) or sham (n=42); baseline clinical characteris-
tics did not differ significantly between the groups. In the RDN 
group, patients received on average 43.8±13.1 ablations in total 
with the majority of ablations directed to the branch vessels 
(25.9±12.8) as compared with the main arteries (17.9±10.5). 
This represents four times the number of ablations delivered 
to each patient in Symplicity HTN-3. Despite great care being 
taken to ensure medication stability throughout the study, three 
patients in the RDN group and five patients in the control group 
were found to be taking antihypertensive medication at baseline 
according to the results of drug testing. Overall compliance with 
the requirement to be off medication throughout the study was 
85%.
The first interim analysis at 3 months postrandomisation 
showed a significant reduction in both office and ambulatory 
BP (ABP) in the RDN group: 24 hours ASBP –5.5 mm Hg (95% CI 
–9.1 to –2.0; p=0.0031), 24 hours ambulatory DBP (ADBP) 
–4.8 mm Hg (–7.0 to –2.6; p<0.0001), office SBP  –10.0 mm Hg 
(–15.1 to –4.9; p=0.0004) and office DBP –5.3 mm Hg (–7.8 to 
–2.7; p=0.0002)16 (figure 1). There were no significant changes 
in the sham group and thus the mean difference between the 
groups favoured RDN for both office and 24 hours ABP (ABP) 
reduction from baseline with baseline-adjusted analyses also 
confirming these findings. Marked heterogeneity of BP response 
was noted in both treatment and sham control groups and more 
than half of the RDN group exhibited reduction in 24 hours 
ASBP of >10 mm Hg. Importantly, no major procedural or 
clinical safety events were noted in either group throughout the 
3 months.
Figure 1 24 hours ambulatory systolic blood pressure reduc-
tion in Spyral HTN-OFF MED and HTN-ON MED, RADI-
ANCE-HTN SOLO and SYMPLICITY HTN-3 randomised 
clinical trials. Data shown as mean±SEM. Δ, change from 
baseline; ASBP, ambulatory systolic blood pressure; 
RDN, renal denervation.
figure 1 24 Hour ambulatory systolic blood pressure reduction in Spyral HTN-OFF MED and HTN-ON MED, RADIANCE-HTN SOLO and SYMPLICITY 
HTN-3 randomized clinical trials. Data shown as mean±SEM. (Δ=change from baseline; ASBP=Ambulatory systolic blood pressure; RDN=renal 
denervation). 
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spyRaL hTn-on mEd
In this global multicentre randomised sham-controlled study, the 
investigators aimed to assess the safety and efficacy of RF RDN 
in patients between the ages of 20 and 80 years with mild-to-
moderate hypertension already on treatment with 1-to-3 stan-
dard antihypertensive medications.18 BP enrolment criteria were 
the same as for SPYRAL HTN-OFF MED with the intention 
to exclude patients with isolated systolic hypertension. Drug 
adherence was monitored through use of HPLC and mass spec-
troscopy of urine and plasma samples at baseline and follow-up 
visits, complemented by observed tablet taking prior to ambula-
tory blood pressure monitoring at each visit. Patients who met 
all the inclusion criteria were randomly assigned to either RDN 
or sham in a 1:1 ratio after a renal angiogram with similar efforts 
to blind patients and assessors as in SPYRAL HTN-OFF MED, 
with maintenance of blinding for up to 12 months following 
randomisation.
Patients were treated with RDN or underwent sham control 
procedure exactly as described in the SPYRAL HTN-OFF 
MED section and returned for office follow-up visits at 1, 3 
and 6 months. Antihypertensive medication changes were not 
allowed for 6 months following randomisation unless escape 
criteria were met. From a total of 467 screened and enrolled 
patients, the investigators reported a prospectively planned 
interim analysis on the first 80 patients randomly assigned to 
RDN (n=38) or sham control (n=42). Clinical characteristics 
and mean office and ABP parameters did not differ between the 
groups. There were no differences in either the number of anti-
hypertensives prescribed between the groups nor in the distri-
bution of the classes of antihypertensive medications. Patients 
treated with RDN received 45.9±13.7 ablations in total with 
19.3±8.9 ablations in the main arteries and 26.6±11.7 ablations 
in the branches.
There were no powered end points in this study and anal-
ysis was undertaken on an intention-to-treat basis. Effective 
masking of patients to randomisation allocation was achieved 
and demonstrated through the use of a blinding index at 3 and 
6 months follow-up. The change in ABP was significantly greater 
at 6 months in the RDN group than the sham control group: 
for 24 hours ASBP (difference –7.4 mm Hg, –12.5 to –2.3; 
p=0.0051) and 24 hours ADBP (difference –4.1 mm Hg, –7.8 to 
–0.4; p=0.0292) (figure 1). Furthermore, significantly greater 
changes in the RDN group compared with the sham group were 
seen for office SBP (difference –6.8 mm Hg, 95% CI –12.5 to 
–1.1; p=0.0205) and office DBP (difference –3.5 mm Hg, –7.0 
to –0.0; p=0.0478). Differences in 24 hours ASBP and ADBP 
were not significant between the groups at 3-month follow-up 
and a progressive trend in reduction in office and ABP was 
demonstrated from 3 to 6 months. In this study, assessment of 
adherence to antihypertensive drugs revealed some surprising 
findings with non-prescribed antihypertensives being detected 
in 10%–15% of all patients at each timepoint. In addition, 
adherence with prescribed therapy was only ~60% with highly 
variable patient adherence at all timepoints. There were insuf-
ficient numbers of patients in each group for a meaningful per 
protocol analysis which would have excluded patients meeting 
escape criteria and non-adherent patients. Once again, this study 
demonstrated the safety of RF RDN with no procedural or clin-
ical events through 6 months of follow-up.
RadianCE soLo sTUdy
A novel RDN platform utilising US energy to thermally ablate 
the renal sympathetic nerves has recently been developed 
(Paradise RDN System; ReCor Medical, Palo Alto, CA, USA).19 
The technology consists of an ablation catheter with a low-pres-
sure water-filled cooling balloon containing a ceramic US trans-
ducer delivering radial energy and an automated customised 
power generator. The design permits circumferential ablation at 
a depth of 1–6 mm with reduced endothelial damage in contrast 
to RF ablation (depth 0–4 mm) with concomitant local endo-
thelial destruction. Also, in contrast to RF energy catheters, the 
Paradise System is currently intended for use in the main renal 
arteries and large accessory vessels (>4 mm diameter) only.
The RADIANCE SOLO study was an international multicentre 
single blind randomised sham-controlled trial undertaken in US 
and European centres aiming to evaluate the safety and efficacy 
of the Paradise System in non-medicated patients with primary 
hypertension.20 Similar to the SPYRAL programme studies, this 
was an off-medication trial partnered with a study in patients 
with RHTN taking a fixed combination triple antihypertensive 
(RADIANCE TRIO) which is still recruiting patients ( Clinical-
Trials. gov Identifier: NCT02649426). However, both SOLO 
and TRIO studies were independently powered for their primary 
endpoints, based on the incremental BP-lowering effects seen 
with RDN in the DENER-HTN study. The SOLO study enrolled 
men and women between the ages of 18 and 75 years with either 
uncontrolled hypertension taking 0–2 antihypertensive drugs or 
with controlled hypertension taking 1–2 drugs. During a 4-week 
run-in period, any participants taking antihypertensive medica-
tions were required to wash out these medications. At the end of 
the run-in period, all patients were required to meet ABP criteria 
(daytime BP ≥135/85 and <170/105 mm Hg) prior to randomi-
sation, on no prescribed antihypertensive medications.
Patients were randomised 1:1 to receive either RDN or sham 
control with patients, assessors and follow-up visit physicians 
remaining blinded to treatment allocation for 6 months postrando-
misation. Efforts were made to maintain blinding through the use 
of periprocedural sensory masking and this was successful according 
to the results of the Bang and James blinding indices. In total, 803 
patients were enrolled of whom 633 were excluded mostly due to 
failure to meet BP criteria. Ultimately, 170 patients proceeded to renal 
angiography of whom 146 met the anatomical criteria for randomi-
sation: 74 were allocated to RDN and 72 to sham control. There 
were no significant differences in baseline characteristics between 
the groups. Per protocol denervation required a minimum of two 
US activations per renal artery and a maximum of three per vessel. 
Those randomised to treatment with US RDN in SOLO received an 
average of 5.4 (SD 1.0) US emissions in total, bilaterally. There was 
no difference between the groups in postprocedure pain. The reduc-
tion in daytime ASBP was greater in the RDN group (–8.5 mm Hg, 
SD 9.3) than in the sham control group (–2.2 mm Hg, SD 10.0; 
baseline-adjusted difference between groups: –6.3 mm Hg, 95% CI 
–9.4 to –3.1, p=0.0001) (figure 1). Per protocol analysis suggested 
that the small numerical sham BP differences were observed princi-
pally in those patients who had restarted medications and not in the 
group who remained off meds in the sham arm. Secondary endpoint 
analysis demonstrated significant reductions in office and home SBP 
and DBP in the RDN group compared with the sham group. No 
major adverse events were reported in either group.
oThER EvidEnCE ThaT sUggEsTs Rdn may bE 
bEnEfiCiaL foR RhTn
sham-controlled studies
To date, 1113 patients have been studied in randomised 
sham-controlled trials of RDN using either RF or US tech-
nologies (table 1). Of these studies only the aforementioned 
SPYRAL programme and RADIANCE-HTN SOLO study and 
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the REDUCE HTN: REINFORCE trial ( ClinicalTrials. gov 
Identifier: NCT02392351) were conceived in accordance with 
updated recommendations for design of clinical trials of RDN in 
the wake of the negative SYMPLICITY HTN3 study.
The REDUCE HTN: REINFORCE study used a bipolar RF 
over-the-wire low-pressure balloon catheter with 4–8 helically 
spaced, simultaneously activated electrodes (depending on 
catheter size) to achieve circumferential denervation with no 
more than two 30 s applications per artery. Following a 4-week 
washout period, non-medicated patients between the ages of 
18 and 75 years with office SBP between 150 and 180 mm Hg 
(and ASBP of 135–170 mm Hg) were randomised to RDN or 
control in a 2:1 ratio and no medication changes were allowed 
prior to the primary endpoint at 8 weeks.21 The study was termi-
nated prematurely on the basis of futility following an interim 
analysis instigated by slow enrolment, which showed that the 
primary end point could not be met. Although there were no 
procedural or clinical safety concern and despite the fact that 
follow-up of the 51 enrolled patients showed significant office 
and ASBP reduction at 6 months in treated patients compared 
with controls, the sponsor (Boston Scientific) has to date not 
indicated if it will continue with its RDN programme.
Randomised controlled trials without sham procedure
There have been 10 randomised controlled trials (RCTs) of RDN 
to date, mostly designed and initiated prior to SYMPLICITY 
HTN3, half of which were small in size (<100 patients) and 
2 of which were prematurely terminated (table 2). Of these, 
the DENERHTN study, an investigator-led trial funded by 
the French Ministry of Health, was one of the earlier RCTs to 
show the efficacy of RF RDN in patients with RHTN despite 
using the original ablation procedure with patients receiving 
a median number of six ablations in the right renal artery and 
five in the left.22 The study was also important in demonstrating 
that a standardised approach to managing medications using 
a triple antihypertensive regimen at the outset (indapamide 
1.5 mg, ramipril 10 mg or irbesartan 300 mg, amlodipine 10 mg 
daily), followed by a standardised stepped care antihyperten-
sive regimen, could be used in both RDN and control groups 
to effectively ensure that both cohorts were equally and stably 
medicated throughout the study. The same investigators went 
on to later report a high prevalence of non-adherence to anti-
hypertensive drugs in DENERHTN (50% in both cohorts) 
despite very close scrutiny from investigators throughout the 
study although this did not influence the primary endpoint 
outcome.23
The RADIOSOUND-HTN trial was the first study to investi-
gate the efficacy of RDN using different procedural approaches 
and technologies.24 Patients with RHTN were randomised in a 
1:1:1 ratio to receive RF RDN to the main renal arteries (RFM-
RDN) or RF RDN to the main renal arteries, side branches and 
accessories (RFB-RDN) or endovascular US RDN to the main 
renal arteries (USM-RDN). RF ablation was performed using the 
Symplicity Spyral catheter and US ablation was undertaken using 
the Paradise RDN system. In total 120 patients were enrolled 
with a mean daytime ABP 153/86±12/13 mm Hg. Of these, 39 
were randomised to RFM-RDN, 39 to RFB-RDN and 42 to 
USM-RDN. At 3 months, daytime ASBP reduction was similar 
between the USM-RDN and RFB-RDN groups but was signifi-
cantly greater in the USM-RDN group than in the RFM-RDN 
group (−13.2±13.7 vs −6.5±10.3 mm Hg, mean difference 
−6.7 mm Hg, global p=0.038 by ANOVA, adjusted p=0.043). 
Although this was a single centre study, the treatment effects 
were similar to those reported in the previously described 
SPYRAL and SOLO studies and once again no safety signal was 
observed. The study findings confirm earlier data that suggest 
that RF RDN targeting both main renal artery and branches 
is required to achieve more complete renal sympathectomy as 
measured by reduction in renal norepinephrine tissue content 
and renal cortical axon density.12 Clearly further studies are now 
required to compare the efficacy and cost effectiveness of US 
and RF RDN.
Table 1 Randomised sham-controlled trials of renal denervation in humans
study name and (year)
ClinicalTrials.gov identifier
no of 
patients Experimental design hypertension phenotype
denervation technology and 
number of ablations primary bp endpoint
Change in primary Ep
(mm hg)
p for baseline-adjusted 
treatment difference
RADIANCE HTN-SOLO20 
(2018)
NCT02649426
146 Multicentre RCT: single blind 
(participant)
Sham: renal angiogram
Combined mild–moderate 
systolic–diastolic HTN: off 
meds
PARADISE balloon cooled
US catheter
5 US emissions per patient
Daytime ASBP reduction at 
8 weeks
RDN −8.5 SHAM 
−2.2 p=0.0001
REDUCE-HTN: 
REINFORCE21(2018)
NCT02392351
51 Multicentre RCT: single blind 
(participant)
Sham: renal angiogram
Mild–moderate systolic HTN: 
off meds
Vessix balloon catheter, helical 
bipolar RF electrodes
14 ablations per patient
24 hours ASBP reduction at 
8 weeks
RDN −5.3 SHAM −8.5 p=0.08
(interim analysis)
SPYRAL ON MED18 (2018)
NCT02439775
80 Multicentre RCT: single blind 
(participant)
Sham: renal angiogram
Combined mild–moderate 
systolic–diastolic HTN: on 
meds
SPYRAL multielectrode
RF catheter
46 ablations per patient
24 hours ASBP reduction at 
6 months
RDN −9.0 SHAM −1.6
p=0.006
SPYRAL OFF MED16 (2017)
NCT02439749
80 Multicentre RCT: single blind 
(participant)
Sham: renal angiogram
Combined mild–moderate 
systolic–diastolic HTN: off 
meds
SPYRAL multielectrode
RF catheter
44 ablations per patient
24 hours ASBP reduction at 
3 months
RDN −5.5 SHAM −0.5
p=0.04
WAVE IV38 (2016)
NCT02029885
81 Multicentre RCT: double 
blind,
Sham: diagnostic US
Mild–moderate systolic HTN: 
on meds
External low intensity focused 
US,
14 US emissions per artery
Office SBP reduction at 
6 months
RDN −12.9 SHAM −22.7
p=0.13
(interim analysis)
RESET39 (2016)
NCT01459900
69 Single centre RCT: double 
blind,
Sham: renal angiogram
Mild–moderate systolic HTN: 
on meds
Unipolar Symplicity Flex
RF catheter
10 ablations per patient
Daytime ASBP reduction at 
3 months
RDN −6.2 SHAM −6.0
p=0.95
RDN in mild resistant HTN40 
(2015)
NCT01656096
71 Single centre RCT: double 
blind,
Sham: renal angiogram
Mild systolic HTN: on Meds Unipolar Symplicity Flex
RF catheter
11 ablations per patient
24 hours ASBP reduction at 
6 months
RDN −7.0 SHAM −3.5
p=0.15
Symplicity HTN37 (2014)
NCT01418261
535 Multicentre RCT: single blind 
(participant)
Sham: renal angiogram
Moderate–severe systolic HTN: 
on meds
Unipolar Symplicity Flex
RF catheter
11 ablations per patient
Office SBP reduction at 
6 months
RDN −14.1 SHAM −11.3
p=0.26
The term resistant hypertension has not been used as these trials did not apply the current definition of resistant hypertension as inclusion criteria.35
ASBP, ambulatory systolic blood pressure; HTN, hypertension; RCT, randomized controlled trial; RF, radiofrequency; SBP, systolic blood pressure; US, ultrasound. 
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non-randomised studies (registries)
A number of registry studies of RDN exist with >4000 patients 
enrolled and treated to date utilising different ablation technolo-
gies but with the majority of patients in each being treated with 
RF RDN using the unipolar Symplicity catheter and the original 
proximal renal artery procedural approach. Importantly, none of 
these registries has identified either a procedural or a renovas-
cular safety signal, although renovascular surveillance has been 
less rigorously scrutinised than in the randomised clinical trials. 
JUKS have limited consideration to the largest three of these 
non-randomised studies.
The Global Symplicity Registry (GSR) is a multicentre study 
which has provided valuable data on the efficacy and safety of 
RF RDN in >2500 patients with uncontrolled hypertension in 
a real world setting.25 Initial reports demonstrating clinically 
meaningful office and ABP (and heart rate) reduction at 6 and 
12 months are now published as well as data indicating an atten-
uated effect of RDN in patients with isolated systolic hyperten-
sion.26–28 Another report from this registry has shown that at 
12 months after treatment, RDN was associated with a signifi-
cant improvement in health-related quality of life measures and 
in particular reduction in anxiety/depression.29 More recently, 
GSR data have been presented at the European Society of 
Cardiology 2018 meeting demonstrating durable office and 
24 hours ASBP reduction (16 and 9 mm Hg, respectively) out 
to 3 years following treatment (manuscript in press, European 
Heart Journal).
In the UK Renal Denervation Affiliation study, investigators 
reported the effect of RDN in 253 patients with uncontrolled 
hypertension from 18 UK centres.30 Eighty-one per cent of 
patients were treated with the Symplicity Flex catheter. Mean 
follow-up duration was 11 months for office BP which fell by 
22/9 mm Hg and 8.5 months for daytime ABP which fell by 
12/7 mm Hg, with reduced response noted in the lowermost 
quartile of starting BP. The fall in BP was independent of medi-
cation changes and aldosterone antagonist use did not affect 
response.
In Sweden, 252 hypertensive patients treated with RDN 
between 2011 and 2015 were followed up in a national registry 
for up to 36 months.31 More than 90% of patients were treated 
with RF RDN of which 60% had Symplicity Flex and utilised 
the older procedural technique of proximal main renal artery 
denervation. Despite this, significant reductions in office and 
24 hours mean ASBP (15 and 8 mm Hg, respectively) were 
noted at 6 months and persisted at 36 months follow-up without 
change in antihypertensive medications. No significant safety 
Table 2 Randomised trials of renal denervation in humans without sham
study name and (year)
ClinicalTrials.gov identifier
no of 
patients Experimental design hypertension phenotype
denervation technology and 
no of ablations primary bp endpoint
Change in primary Ep 
(mm hg)
p for baseline-adjusted 
treatment difference
RADIOSOUND24 (2018)
NCT02920034
RF vs US RDN
120 Single centre three arm 
randomised trial: single 
blind
Moderate systolic HTN: 
on meds
SPYRAL multielectrode RF 
catheter:
17/35 ablations per patient 
(RFM-RDN/RFB-RDN)
PARADISE balloon cooled US 
catheter: 6 ablations per patient
Daytime Mean ASBP 
reduction at 3 months
RFM-RDN −6.5
RFB-RDN −8.3
US −13.2
p only significant for US vs 
RFB-RDN
RDN OSA41 (2018)
NCT01366625
RDN vs standard 
pharmacotherapy in patients 
with moderate to severe OSA
60 Single centre RCT: open 
label, blinded endpoint 
evaluation
Moderate systolic HTN: 
on meds
Moderate–severe OSA
Unipolar Symplicity Flex
RF catheter
12 ablations per patient
Office SBP reduction at 
3 months
RDN −22.0 Control −5.0
p=0.002
INSPiRED42 (2017)
NCT01505010
RDN vs standard 
pharmacotherapy
15 Three centre RCT: open 
label, blinded endpoint 
evaluation
Combined mild–moderate 
systolic–diastolic HTN: 
on meds
EnligHTN multielectrode
RF catheter
8–24 ablations per patient
24 hours ASBP reduction at 
6 months
RDN −21.7 Control 0.7
p=0.018
SYMPATHY43 (2017)
NCT01850901
RDN vs standard 
pharmacotherapy
139 Multicentre RCT: open label, 
blinded endpoint evaluation
Moderate–serve systolic 
HTN: on meds
EnligHTN multielectrode or 
Symplicity Flex RF catheters
15 ablations per patient
Daytime Mean ASBP 
reduction at 6 months
RDN −6.0 Control −7.9
p=0.625
DENERVHTA44 (2016)
NCT02039492
RDN vs spironolactone
24 Three centre RCT: open 
label, blinded endpoint 
evaluation
Moderate–severe systolic 
HTN: on meds
Unipolar Symplicity Flex
RF catheter:
8–12 ablations per patient
24 hours ASBP reduction at 
6 months
RDN −5.7 Control −23.6
p=0.01
PRAGUE-1545 (2015)
NCT 01560312
RDN vs optimised 
pharmacotherapy
106 Multicentre randomised 
trial, open label, blinded 
endpoint evaluation
Moderate systolic HTN: 
on meds
Unipolar Symplicity Flex
RF catheter:
11 ablations per patient
24 hours ASBP reduction at 
6 months
RDN −8.8 Control −8.1
p=0.87
DENER-HTN22 (2015)
NCT01570777
RDN vs optimised 
pharmacotherapy
106 Multicentre RCT: open label, 
blinded endpoint evaluation
Moderate–severe systolic 
HTN: on meds
Unipolar Symplicity Flex
RF catheter:
11 ablations per patient
Daytime Mean ASBP 
reduction at 6 months
RDN −15.8 Control −9.9
p=0.03
HTN JAPAN46 (2015)
NCT01644604
RDN vs standard 
pharmacotherapy
41 Multicentre randomised 
trial, open label, blinded 
endpoint evaluation
Severe systolic HTN: on 
meds
Unipolar Symplicity Flex
RF catheter:
11 ablations per patient
Office SBP reduction at 
6 months
RDN −16.6 Control −7.9
p=0.169
Early termination due to
Symplicity HTN-3 result
RDN OSLO47 (2013)
NCT01673516
RDN vs optimised 
pharmacotherapy
20 Single centre RCT, open 
label, blinded endpoint 
evaluation
True treatment resistant 
HTN
Unipolar Symplicity Flex
RF catheter:
8 ablations per artery
Office SBP reduction at 
6 months
RDN −8.0 Control −28.0
p=0.08
Early termination (ethical 
reasons)
Symplicity HTN-25 (2010)
NCT00888433
RDN vs standard 
pharmacotherapy
106 Multicentre RCT: open label, 
blinded endpoint evaluation
Severe systolic HTN Unipolar Symplicity Flex
RF catheter:
8–12 ablations per patient
Office SBP reduction at 
6 months
RDN −32 Control 1
p=0.0001
ASBP, ambulatory systolic blood pressure; HTN, hypertension; RCT, randomised controlled trial; RF, radiofrequency; RFB-RDN, radiofrequency renal denervation to main renal artery, branches and accessories; 
RFM-RDN, radiofrequency renal denervation to main renal artery; SBP, systolic blood pressure; US, ultrasound.
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concerns arose and renal function remained stable throughout 
follow-up.
ThE Us food and dRUg adminisTRaTion pERspECTivE 
on dEviCE ThERapy of hypERTEnsion
The US Food and Drug Administration (FDA) convened an 
advisory panel in Washington (05/12/2018) comprising FDA 
members, device manufacturers and clinicians, to discuss the 
approval process and requirements for device-based therapies 
for hypertension.32 While this panel meeting was not focused 
on data review, its main objective was to clarify the path forward 
for device therapies of hypertension including RDN. The discus-
sants agreed on the following points:
1. It is appropriate to study RDN in further clinical trials utilis-
ing both the ‘off ’ meds and ‘on’ meds study design. A RDN 
registry (with evaluation of renal function) and postmarket-
ing evaluation would also be critical to determine long-term 
safety, clinical outcomes and provide an opportunity to ex-
amine subgroups.
2. Sham control remains the most rigorous way to study RDN 
unless clinically impossible. However, cross-over studies 
were not felt to be helpful given the possibility of confound-
ing.
3. It is critical to continue to focus on safety: procedural, re-
novascular and renal function safety comparisons between 
groups (active therapy and sham control) and to a perfor-
mance goal.
4. To determine efficacy, ABP should remain the endpoint for 
clinical studies, with recommendation that a 5–7 mm Hg de-
crease in ASBP is meaningful and that 12-month durability of 
BP lowering efficacy should be demonstrated.
5. Reduction in medication burden was felt to be clinically 
meaningful and also addressed an area of unmet need: the 
importance of accruing data on patients’ preferences for 
treatment of their long-term condition with drug/non-drug 
therapy.
ThE JUKs UpdaTEd pERspECTivE on Rdn
The SPYRAL and RADIANCE study programmes to date have 
provided encouraging data to suggest that RDN may have a 
role in the treatment of hypertension. Moreover, these trials 
have shown the value of collaboration between hypertension 
specialists, interventionalists and industry to design high quality, 
rigorously executed clinical trials which have moved the field 
forward and rekindled enthusiasm for RDN in the clinical 
community. However, these studies have limitations: they are of 
short duration, included a small number of patients, and longer 
term follow-up has not been published as yet. In addition, the 
studies reported considerable heterogeneity in the response 
to RDN, leaving open the question of which patients may be 
best responders to the therapy. Finally, at present, it is unclear 
which technology may be best for RDN, with RF and US systems 
appearing more or less similar in efficacy and ongoing trials of 
chemical ablation systems are not published yet.
To date, the NICE has not updated the guidance originally 
produced in 2012 regarding RDN (IPG418) which deemed that 
there were insufficient data to support the routine use of RDN 
but that patients could be offered the procedure in the context of 
audit/research with a firm recommendation for data collection 
and publication of outcomes in all patients treated with RDN.33 
In July 2016, NHS England decided that RDN would not be 
routinely commissioned due to lack of clinical effectiveness on 
the basis of the Symplicity HTN-3 outcome and secondary lack 
of cost effectiveness data.34 Subsequently, the 2018 European 
Society of Cardiology-European Society of Hypertension  (ESC-
ESH) guideline for the management of arterial hypertension 
mandated that routine use of any device therapy for hyperten-
sion was not recommended outside the context of clinical trials 
Table 3 Research agenda to determine the role of renal denervation in clinical practice
Research priority Considerations
Pivotal studies and additional registry data to 
determine role of RDN in treatment of hypertension
 ► It is critical to understand the effect of RDN in patients both on and off medications and given that current studies 
have been small in size, larger scale sham-controlled clinical trials (with powered endpoints) are needed with rigorous 
evaluation of medication usage.
 ► Using ABP for endpoints is mandatory but office BP should also be collected and home BP where possible (with strict 
patient instructions to avoid using home BP data to adjust their medication regimens).
 ► It may be difficult to recruit patients without the promise of a cross-over opportunity.
 ► An outcome trial would be desirable, though there would be considerable challenges to achieving this and the cost 
would be enormous.
Establish the durability/safety of the different RDN 
technologies
 ► Longer term follow-up to determine procedural, renal artery and renal safety is necessary as well as to determine 
durability of effect.
 ► The possibility of functional renal nerve regrowth can be assessed.48
 ► Are there differences between the energy modalities in terms of efficacy/safety/durability?
Is RDN cost-effective?  ► Modelling cost-effectiveness will require larger datasets and hopefully as these begin to emerge, the cost of the RDN 
procedure may have started to diminish due to market forces/competing technologies.
What is the mechanism of action?  ► This remains to be clarified and the role of afferent/efferent renal sympathetic signalling and selective afferent/efferent 
sympathectomy should be addressed.49
Which patients are best responders?  ► Heterogeneity of response is observed with all drug and device therapy—what does this mean and can true responders/
non-responders be defined?
 ► Even partial responders may benefit significantly from RDN if there are no other treatment options.
Can procedural markers of success be defined and 
will they be of value?
 ► Novel technologies are providing insights into how to achieve successful ablation procedure through renal nerve 
mapping but presently add considerably to time spent on the table in the catheter lab and their value is undetermined.50
Of interest, not critical for hypertension indication
Is RDN useful for other sympathetically mediated 
diseases?
 ► Conditions such as heart failure, obstructive sleep apnoea and chronic kidney disease are all characterised by increased 
sympathetic signalling and may respond to RDN.
Is lowering of BP the best biomarker of a successful 
RDN procedure?
 ► If an RDN procedure does not lower BP by a clinically significant amount, it remains of interest to understand if there 
may be other benefits (eg, regression of LVH, improved glycaemic parameters, reduction in arterial stiffness).51–54
BP, blood pressure; LVH, left ventricular hypertrophy; RCT, randomised clinical trial; RDN, renal denervation.
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(class II recommendation, grade B level of evidence).35 It is worth 
pointing out that the most recent studies from the SPYRAL and 
RADIANCE programmes were not considered at the time of 
the European guidelines writing and that in July 2018, the ESH 
Working Group on interventional treatment of hypertension 
published a position paper that followed the recommendation 
of the 2018 ESC-ESH guideline and outlined further research 
questions to be addressed.36
Having considered the evidence reviewed earlier in this 
document, the JUKS also have concluded that there are insuffi-
cient data at present to suggest that RDN should be considered 
routine standard of care in the management of hypertension in 
adults and that additional clinical trials data are required. There 
are several important areas of research that should be considered 
as next steps and a research agenda has been defined (table 3). 
It is important to recognise that the use of interim analyses in 
both SPYRAL studies may have led to overestimation of effect 
size (type I error) and such an approach is strongly discouraged 
for future studies.37 The recent focus on patient preference for 
non-drug treatments should also be considered in the design of 
future studies. The latter should act as a stimulant to those who 
look after patients with hypertension to consider referring their 
patients to centres undertaking RCTs of the therapy.
ConCLUsions
Hypertension remains a global health issue and better means 
to diagnose, treat and control hypertension in the long term 
are urgently required. Increasing evidence indicates that many 
patients struggle to maintain healthy lifestyles and are non-ad-
herent to pharmacological measures to control BP in the long 
term. Although further research is needed on the best ways to 
ensure compliance, such individuals might therefore choose to 
have a device treatment, if proven durably safe and effective, 
in preference to lifelong drug therapy. The JUKS concludes 
that there is insufficient evidence to recommend routine use of 
RDN for hypertension at the present time and that use of RDN 
should remain restricted to clinical trials. However, we support 
the ongoing clinical trials programmes from the different device 
manufacturers across the spectrum of RDN technologies and 
strongly encourage clinicians who look after patients with hyper-
tension to inform their patients about these studies which are 
recruiting participants who are on or off medications in order to 
inform future practice*.
*Active RDN clinical trial programmes with details of local 
recruiting centres are listed below:
Ablative Solutions Ltd. https:// clinicaltrials. gov/ ct2/ show/ 
NCT02910414
Medtronic: https:// clinicaltrials. gov/ ct2/ show/ NCT02439749
ReCor Medical: https:// clinicaltrials. gov/ ct2/ show/ 
NCT03614260
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